Frequency Therapeutics has raised $32 million to help finance the development of its therapy for noise-induced hearing loss. The Woburn, Massachusetts-based firm specialises in small molecule ...

Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...

Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.